


CLASSIFICATION OF SUBJECT MATTER C 7 C12Q1/68 G01N G01N33/74 G01N33/68 IPC 7 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) C12Q G01N IPC 7 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) CHEM ABS Data, BIOSIS, EPO-Internal, MEDLINE, WPI Data, EMBASE C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages Category ° 1-3,11"Interleukin-10 promoter LIO D ET AL: P,X polymorphism in sporadic Alzheimer's disease." GENES AND IMMUNITY, vol. 4, no. 3, April 2003 (2003-04), pages 234-238, XP001155652 ISSN: 1466-4879 (ISSN print) page 236; tables 1,2 1-17 "Patients with Υ REMARQUE E J ET AL: Alzheimer's disease display a pro-inflammatory phenotype" EXPERIMENTAL GERONTOLOGY vol. 36, no. 1, January 2001 (2001-01), pages 171-176, XP002257920 ISSN: 0531-5565 page 173 -page 175; table 1 -/--Patent family members are listed in annex. Further documents are listed in the continuation of box C. *T* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the Special categories of cited documents: *A* document defining the general state of the art which is not considered to be of particular relevance invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone 'E' earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) 'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled O document referring to an oral disclosure, use, exhibition or other means document published prior to the International filing date but later than the priority date claimed "&" document member of the same patent family Date of mailing of the international search report Date of the actual completion of the international search 10/11/2003 15 October 2003 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016

Trommsdorff, M



	Relevant to claim No.	
Citation of document, with indication, where appropriate, or the relevant passages		
TURNER D M ET AL: "AN INVESTIGATION OF POLYMORPHISM IN THE INTERLEUKIN-10 GENE PROMOTER" EUROPEAN JOURNAL OF IMMUNOGENETICS, OXFORD, GB, vol. 24, no. 1, 1997, pages 1-8, XP000865679 ISSN: 0960-7420 page 6; figure 1	1–17	
PAPASSOTIROPOULOS ANDREAS ET AL: "Genetics of interleukin 6: Implications for Alzheimer's disease" NEUROBIOLOGY OF AGING, vol. 22, no. 6, November 2001 (2001-11), pages 863-871, XP002257921 ISSN: 0197-4580 page 867, left-hand column -page 868, left-hand column	3,10	
WO 95 33992 A (MOR RESEARCH APPLIC LTD; UNIV BAR ILAN (IL); SHALIT FRANCES (IL)) 14 December 1995 (1995-12-14) figures 1-6	3,10	
MARTIN E R ET AL: "SNPING AWAY AT COMPLEX DISEASES: ANALYSIS OF SINGLE-NUCLEOTIDE POLYMORPHISMS AROUND APOE IN ALZHEIMER DISEASE" AMERICAN JOURNAL OF HUMAN GENETICS, AMERICAN SOCIETY OF HUMAN GENETICS, CHICAGO, IL, US, vol. 67, August 2000 (2000-08), pages 383-394, XP000995224 ISSN: 0002-9297 page 384 -page 385	3,10	
DEPBOYLU CANDAN ET AL: "Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease." NEUROSCIENCE LETTERS, vol. 342, no. 1-2, 15 May 2003 (2003-05-15), pages 132-134, XP001155649 ISSN: 0304-3940 (ISSN print) the whole document /		
	POLYMORPHISM IN THE INTERLEUKIN-10 GENE PROMOTER" EUROPEAN JOURNAL OF IMMUNOGENETICS, OXFORD, GB, vol. 24, no. 1, 1997, pages 1-8, XP000865679 ISSN: 0960-7420 page 6; figure 1 PAPASSOTIROPOULOS ANDREAS ET AL: "Genetics of interleukin 6: Implications for Alzheimer's disease" NEUROBIOLOGY OF AGING, vol. 22, no. 6, November 2001 (2001-11), pages 863-871, XP002257921 ISSN: 0197-4580 page 867, left-hand column -page 868, left-hand column WO 95 33992 A (MOR RESEARCH APPLIC LTD ;UNIV BAR ILAN (IL); SHALIT FRANCES (IL)) 14 December 1995 (1995-12-14) figures 1-6 MARTIN E R ET AL: "SNPING AWAY AT COMPLEX DISEASES: ANALYSIS OF SINGLE-NUCLEOTIDE POLYMORPHISMS AROUND APOE IN ALZHEIMER DISEASE" AMERICAN JOURNAL OF HUMAN GENETICS, CHICAGO, IL, US, vol. 67, August 2000 (2000-08), pages 383-394, XP000995224 ISSN: 0002-9297 page 384 -page 385 DEPBOYLU CANDAN ET AL: "Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer's disease." NEUROSCIENCE LETTERS, vol. 342, no. 1-2, 15 May 2003 (2003-05-15), pages 132-134, XP001155649 ISSN: 0304-3940 (ISSN print) the whole document	



PCT/tra 0 369

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT							
ategory ° Cilallon of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	- 3					
SZCZEPANIK A M ET AL: "IL-4, IL-10 and IL-13 modulate ab(1-42)-induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line" JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, XX, vol. 113, no. 1, 2001, pages 49-62, XP002955731 ISSN: 0165-5728 the whole document							
Elle Milote document							
·							



Box I	Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)					
This Inte	mational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:					
1. χ	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: See FURTHER INFORMATION sheet PCT/ISA/210					
2. X	Claims Nos.: 11 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210					
з. 🗌	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).					
Box II	Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)					
This int	ernational Searching Authority found multiple inventions in this international application, as follows:					
1.	As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.					
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.					
з. [As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:					
4.	No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the daims; it is covered by claims Nos.:					
Rema	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.					

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-4 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claims 5-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

With regard to claims 12 and 13 only in vitro methods have been considered.

Continuation of Box I.2


Claims Nos.: 11

Present claim 11 relates to a compound defined by reference to a desirable characteristic or property, namely its ability to modulate IL-10 expression.

The claim covers all compounds having this characteristic or property, whereas the application does not provide support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for any compound with said property. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, no search has been carried out for claim 11.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.







International Application No PCT/GB 03/02369

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9533992 A	14-12-1995	AU 2823895 A EP 0760098 A1 WO 9533992 A1 US 5874312 A	04-01-1996 05-03-1997 14-12-1995 23-02-1999